Breast malignant, males, children
Epidermal Growth Factor Receptor (EGFR)
Reviewer: Monika Roychowdhury, M.D. (see Reviewers page)
Revised: 18 December 2012, last major update January 2012
Copyright: (c) 2001-2012, PathologyOutlines.com, Inc.
● Also called HER1; related to HER2
EGFR expression is associated with these breast cancers:
● Basal-like (BMC Genomics 2007;8:258)
● Metaplastic (76%, Breast Cancer Res 2005;7:R1028), carcinomas with squamous differentiation (87%, Int J Surg Pathol 2005;13:319)
● ER negative tumors (Pathol Res Pract 1988;183:25, Breast Cancer Res 2008;10:R49)
● Phyllodes tumors (all types-19%, malignant-75%, Lab Invest 2006;86:54)
● Sarcoma NOS (5 of 7, Am J Surg Pathol 2006;30:450)
● 6% of breast carcinomas show moderate to low level EGFR amplification associated with protein overexpression, and may be responsive to anti-EGFR therapy (Mod Pathol 2005;18:1027), currently used for lung cancer patients
● EGFR expression is more common in breast tumors in younger and black women
● EGFR expression associated with lower hormone receptor levels, higher proliferation, genomic instability, HER2 overexpression, higher risk of relapse (Cancer 2010;116:1234), poor survival (J Clin Oncol 2007;25:4405)
Metaplastic carcinoma: H&E, EGFR and EGFR-CISH
Spindle cell carcinoma: EGFR and HER2 overexpression
IHC and CISH
Contributed by Dr. Semir Vranic:
Invasive breast carcinoma with squamous features: H&E, EGFR
Malignant phyllodes tumor and EGFR amplification
End of Breast malignant, males, children > Breast cancer > Epidermal Growth Factor Receptor (EGFR)
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at [email protected] with any questions (click here for other contact information).